Klintmalm G, Lönnqvist B, Oberg B, Gahrton G, Lernestedt J O, Lundgren G, Ringdén O, Robert K H, Wahren B, Groth C G
Scand J Infect Dis. 1985;17(2):157-63. doi: 10.3109/inf.1985.17.issue-2.06.
Foscarnet, trisodium phosphonoformate, was administered intravenously to 6 immunosuppressed patients with life-threatening cytomegalovirus infection. Three of the patients were recipients of a kidney and 3 of a bone-marrow transplant. Favourable clinical responses were seen in 5 of the patients, 2 of whom were still in good health 5 and 8 months after the infection had cleared up. No toxic effect of the drug was detected. The results seem to justify further trials, in which foscarnet should be introduced at an earlier stage of the disease.
膦甲酸钠（三钠膦酰甲酸盐）通过静脉注射给予6例患有危及生命的巨细胞病毒感染的免疫抑制患者。其中3例患者接受了肾脏移植，3例接受了骨髓移植。5例患者出现了良好的临床反应，其中2例在感染清除后的5个月和8个月时仍健康状况良好。未检测到该药物的毒性作用。这些结果似乎证明进一步试验是合理的，在试验中应在疾病的更早阶段引入膦甲酸钠。
